Organization (Hospital)
Rochester General Hospital
ClinicalTrials.gov lists Rochester General Hospital as lead sponsor of 11 trials. It has 6 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 0 registered with a 2026 start date. The dashed outline is the pace from the 0 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 0.6 trial starts a year over the five years to September, under the 5 a year the method needs.
Logo Rochester Regional Health, via Wikimedia Commons, CC BY-SA 4.0. Shown to identify the organization; it may be a registered trademark.
This page covers Rochester General Hospital: 11 lead-sponsored trials and 1 legal-entity registration.
Disease areas (14)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Lymphoma | 4 |
| Lymphoma, Non-Hodgkin | 4 |
| Lymphoma, T-Cell, Cutaneous | 3 |
| Mycosis Fungoides | 3 |
| Otitis Media | 3 |
Showing 5 of 14 disease areas.
Trials by start year as sponsor or collaborator (10)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2025 | 1 |
| 2023 | 2 |
| 2021 | 1 |
| 2020 | 1 |
| 2018 | 3 |
| 2017 | 4 |
| 2016 | 1 |
| 2015 | 1 |
| 2013 | 1 |
| 2011 | 1 |
Recruitment duration, a model prediction: 1 trial still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Approved assets (6)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| Oral Vancomycin | 1 |
| Risperidone | 1 |
| Trazodone | 1 |
| HIZENTRA ® | 1 |
| Doxycycline | 1 |
Showing 5 of 6 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 57% hit target (n=7) | 50% on time (n=6) |
Journals published in (52)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| The New England journal of medicine | 8 |
| The Journal of allergy and clinical immunology | 7 |
| The journal of allergy and clinical immunology. In practice | 6 |
| PloS one | 4 |
| British journal of haematology | 3 |
Showing 5 of 52 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 1 | 0 | 1977-03-29 |
Financing and grant events (7)
Shown in this order: most recent first.
| Date | Round type | Amount (USD) | Source |
|---|---|---|---|
| 2025-04-29 | NIH grant | 794,229 | Reporter |
| 2024-11-18 | NIH grant | 404,539 | Reporter |
| 2024-03-15 | NIH grant | 822,233 | Reporter |
| 2022-06-22 | NIH grant | 85,182 | Reporter |
| 2021-07-16 | NIH grant | 89,717 | Reporter |
Showing 5 of 7 events.
FDA inspection record (1)
| Latest classification | Inspections |
|---|---|
| NAI | 8 |
Organization relationships (2)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Rochester Skin Lymphoma Medical Group, PLLC | Co sponsors trial with | 2 |
| Bausch Health Americas, Inc. | Co sponsors trial with | 1 |
Latest dated events (32)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2025-09-29 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-04-29 | NIH grant | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2024-11-18 | NIH grant | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2024-07-11 | FDA inspection | FDA enforcement (warning and untitled letters, recalls, inspections, import refusals, debarment) |
| 2024-03-15 | NIH grant | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
Showing 5 of 32 events.
CLIA clinical laboratory certificates (1)
| Lab | Certificate | Status |
|---|---|---|
| ROCHESTER GENERAL HOSPITAL | Certificate of compliance | Terminated |
Biomarker capability evidence (12)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| APOH | Trial sponsor | Named in trial inclusion criteria |
| CRP | Trial sponsor | Named in trial inclusion criteria |
| PSMB7 | Trial sponsor | Named in trial inclusion criteria |
| G6PD | Trial sponsor | Named in trial exclusion criteria |
| PSMA6 | Trial sponsor | Named in trial exclusion criteria |
Showing 5 of 12 evidence rows.
Biomarkers this organization publishes on (33)
Shown in this order: most publications first.
Showing 5 of 33 biomarkers.
On Scientist.com
Rochester General Hospital is listed as a research supplier in the Scientist.com network.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, active development programs, sec-reported annual financials, fda warning letters, fda untitled letters, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, and workforce and board diversity, as filed.
Work with Rochester General Hospital on Scientist.com
For prices, more details, or to contact Rochester General Hospital, visit Scientist.com.
Sign in to Scientist.com to open this supplier in your organization's marketplace.